Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632371 | 0.93 | WDR5 (0.46) | KMT2AWDR5OPRM1 | |
| SCHEMBL1492681 | 0.93 | WDR5 (0.46) | KMT2AWDR5OPRM1CA12CA1 | |
| SCHEMBL3171333 | 0.91 | WDR5 (0.47) | KMT2AWDR5OPRM1 | |
| SCHEMBL332840 | 0.88 | KMT2A (0.40) | KMT2AWDR5OPRM1OPRL1 | |
| SCHEMBL4442862 | 0.88 | KMT2A (0.40) | KMT2AWDR5OPRM1CA12CA1 | |
| Hydrochloric Acid SCHEMBL29237533 | 0.87 | KMT2A (0.40) | KMT2AWDR5OPRM1CA12CA1 | |
| SCHEMBL2290005 | 0.87 | PDE4A (0.44) | KMT2AWDR5OPRM1 | |
| Hydrochloric Acid SCHEMBL30217436 | 0.87 | KMT2A (0.40) | KMT2AWDR5OPRM1CA12CA1 | |
| SCHEMBL30520809 | 0.86 | KMT2A (0.38) | KMT2AWDR5OPRM1 | |
| SCHEMBL3016883 | 0.84 | CA12 (0.43) | KMT2AWDR5OPRM1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | claimed |
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-04-17 | — | — | US | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-20240300927-A1 | AMIDES AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4410774-A1 | ANTIBACTERIAL COMPOSITION | Seoul National University R&DB Foundation (KR) | 2024-08-07 | — | — | EP | disclosed |
| EP-3577099-B1 | A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4288428-A1 | AMIDES AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1673336-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-05-30 | — | — | EP | disclosed |
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | PHARMACIA & UPJOHN COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
| EP-1673336-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-06-28 | — | — | EP | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-2005019161-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-03-03 | — | — | WO | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SQSTM1, BECN1, ATG7 | KMT2A 3655/4885WDR5 139/4885OPRM1 1599/4885 |
| US-20240300927-A1 | AMIDES AS CBL-B INHIBITORS | CBLB, CBL, CBLC | KMT2A 526/4885WDR5 611/4885OPRM1 3983/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | KMT2A 1976/4885WDR5 450/4885OPRM1 3955/4885 |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | KMT2A 3156/4885WDR5 4299/4885OPRM1 206/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KMT2A 4650/4885WDR5 3150/4885OPRM1 4080/4885 |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | CTSE, CTSS, CTSB | KMT2A 4202/4885WDR5 4274/4885OPRM1 4398/4885 |
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | OXA1L, SOD1, PSEN1 | KMT2A 2600/4885WDR5 1759/4885OPRM1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.